Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2025)

Stoke Therapeutics has reported Long-Term Investments over the past 2 years, most recently at $106.3 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 256.29% year-over-year to $106.3 million; the TTM value through Dec 2025 reached $106.3 million, up 256.29%, while the annual FY2025 figure was $106.3 million, 256.29% up from the prior year.
  • Long-Term Investments for Q4 2025 was $106.3 million at Stoke Therapeutics, up from $80.3 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $107.3 million in Q2 2025 and troughed at $23.0 million in Q1 2025.